Vita
Elena Vita, Gis Sur Yvette FR
Patent application number | Description | Published |
---|---|---|
20110093964 | URANIUM-CHELATING PEPTIDES AND USES THEREOF - The invention concerns uranium-chelating peptides as well as their uses for decontaminating soils and water, and for detecting and treating people contaminated by uranium. Said peptides have a helix-loop-helix type structure comprising the sequence of a calmodulin loop including at least one mutation of neutral residues selected from the group consisting of S, T, C, H, Y, N and Q, of one, two or three residues of at least one of the four calmodulin calcium binding sites: site I: residues selected among D20, D22 and D24 residues; site II: residues selected among D56, D58 and N60 residues; site III: residues selected among D93, D95 and N97 residues; site IV: residues selected among D129, D131 and D133 residues; said positions being indicated with reference to the human calmodulin sequence. | 04-21-2011 |
Elena Vita, Gif-Sur-Yvette FR
Patent application number | Description | Published |
---|---|---|
20090285798 | CD4 MIMIC PEPTIDES AND THEIR USES - An isolated peptide comprising the sequence (I): TPA-Asn-Leu-His-Phe-Cys-Gln-Leu-Xaa | 11-19-2009 |
20100015056 | Uranium-chelating peptides and uses thereof - The invention concerns uranium-chelating peptides as well as their uses for decontaminating soils and water, and for detecting and treating people contaminated by uranium. Said peptides have a helix-loop-helix type structure comprising the sequence of a calmodulin loop including at least one mutation of neutral residues selected from the group consisting of S, T, C, H, Y, N and Q, of one, two or three residues of at least one of the four calmodulin calcium binding sites: site I: residues selected among D20, D22 and D24 residues; site II: residues selected among D56, D58 and N60 residues; site III: residues selected among D93, D95 and N97 residues; site IV: residues selected among D129, D131 and D133 residues; said positions being indicated with reference to the human calmodulin sequence. | 01-21-2010 |
20100303858 | Chimeric HIV-1 Glycoproteins and Their Biological Applications - The invention relates to chimeric HIV-1 gp120 glycoproteins, wherein at least a part of gp120 variable region V1 and/or V2 is replaced by a CD4-derived sequence to obtain the exposition of CD4 induced epitopes or CD4i capable of inducing a specific humoral immune response. Application for the preparation of vaccinal and pharmaceutical composition. | 12-02-2010 |
Francesco Vita, Sant'Anastasia IT
Patent application number | Description | Published |
---|---|---|
20100110429 | METHOD AND APPARATUS FOR MEASURING THE REFRACTIVE INDEX OF A MATERIAL WITH BRAGG GRATINGS - A method for measuring the refractive index of a material with Bragg gratings includes the emission of a collimated radiation beam ( | 05-06-2010 |
Giuseppe Vita, Messina IT
Patent application number | Description | Published |
---|---|---|
20100190733 | Methods of Treating Muscular Dystrophies - The invention relates to methods of treating Duchenne muscular dystrophy with flavonoids. The methods may include (a) providing a pharmaceutical composition comprising a therapeutically effective amount of flavonoid, and (b) administering the composition to a human patient, wherein the flavonoid comprises an isoflav-4-one with at least one of the carbons located at positions 8, 7, 6, 5, 2, 2′, 3′, 4′, 5′, or 6′ modified by an alcohol group. Alternatively, the flavonoid may comprise (1) a flavan-3-ol with at least one of the carbons located at positions 8, 7, 6, 5, 4, 2′, 3′, 4′, 5′, or 6′ modified by an alcohol group, or (2) a Free-B-Ring flavone with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by an alcohol group and with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by a glycoside group. | 07-29-2010 |
20130210753 | METHODS OF TREATING MUSCULAR DYSTROPHIES - The invention relates to methods of treating Duchenne muscular dystrophy with flavonoids. The methods may include (a) providing a pharmaceutical composition comprising a therapeutically effective amount of flavonoid, and (b) administering the composition to a human patient, wherein the flavonoid comprises an isoflav-4-one with at least one of the carbons located at positions 8, 7, 6, 5, 2, 2′, 3′, 4′, 5′, or 6′ modified by an alcohol group. Alternatively, the flavonoid may comprise (1) a flavan-3-ol with at least one of the carbons located at positions 8, 7, 6, 5, 4, 2′, 3′, 4′, 5′, or 6′ modified by an alcohol group, or (2) a Free-B-Ring flavone with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by an alcohol group and with at least one of the carbons located at positions 8, 7, 6, 5 or 3 modified by a glycoside group. | 08-15-2013 |
Joseph A. Vita, Hingham, MA US
Patent application number | Description | Published |
---|---|---|
20100068267 | COMPOSITIONS FOR TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY - The invention provides methods of treating a cardiovascular disease comprising administering a sustained release formulation of hydralazine hydrochloride and at least one of isosorbide dinitrate and/or isosorbide mononitrate in therapeutically effective dosage of each of the aforementioned compounds. | 03-18-2010 |
Marco Tulio Sguerra Vita, Sao Jose Dos Campos - Sp BR
Patent application number | Description | Published |
---|---|---|
20090062973 | STALL, BUFFETING, LOW SPEED AND HIGH ATTITUDE PROTECTION SYSTEM - A flight control system moves elevators according to a pilot command summed with an automatic command. The flight control system monitors a set of flight parameters to determine if the flight vehicle is operating inside a permitted envelope. The flight controls system incorporates automatic protections thru the automatic elevator command if the flight vehicle is close to its envelope limits. The exemplary illustrative non-limiting implementation herein provides automatic protections in order to protect the flight vehicle from low speeds, high attitude, stalls and buffetings. | 03-05-2009 |
20110054720 | STALL, BUFFETING, LOW SPEED AND HIGH ATTITUDE PROTECTION SYSTEM - A flight control system moves elevators according to a pilot command summed with an automatic command. The flight control system monitors a set of flight parameters to determine if the flight vehicle is operating inside a permitted envelope. The flight controls system incorporates automatic protections thru the automatic elevator command if the flight vehicle is close to its envelope limits. The exemplary illustrative non-limiting implementation herein provides automatic protections in order to protect the flight vehicle from low speeds, high attitude, stalls and buffetings. | 03-03-2011 |
Natalio Vita, Saint Gely Du Fesc FR
Patent application number | Description | Published |
---|---|---|
20110201029 | IL-13 RECEPTOR ANTIBODIES - This invention relates to monoclonal and polyclonal antibodies capable of specifically recognizing IL-13 receptor α and uses thereof. | 08-18-2011 |